Drugs / AVX/COVID-12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05205746 | Nov 2021 → Aug 2022 | COVID-19 | Laboratorio Avi-Mex, S.A. de C.V. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2023-05-09 | CastleVax Inc. | Results Avimex interim Phase 3 results showed their NDV-based vaccine, licensed from CastleVax, was effective as a booster against COVID-19. castlevax.com ↗
The Patria® vaccine generates antibodies similar to a vaccine approved by the WHO according to the data available from the Final Stage of Clinical Development, as a booster vaccine. |
| 2023-05-04 | Laboratorio Avi-Mex, S.A. de C.V. | Results La etapa de desarrollo clínico del proyecto VACUNAL PATRIA® arroja datos favorables (AVX/COVID-12) com.mx ↗
La vacuna Patria® genera anticuerpos similares a una vacuna aprobada por la OMS de acuerdo con los datos disponibles de la Etapa Final de Desarrollo Clínico, como vacuna de refuerzo. |
| 2022-08-17 | Laboratorio Avi-Mex, S.A. de C.V. | Results Avances de la Fase Clínica II de proyecto VACUNAL PATRIA® (AVX/COVID-12) com.mx ↗
Los resultados preliminares de la Fase Clínica II de Refuerzo de Patria® (AVX/COVID-12) apuntan hacia un biológico seguro y capaz de estimular la producción de anticuerpos contra SARS-CoV2 en personas ya vacunadas. |
| 2022-02-14 | Laboratorio Avi-Mex, S.A. de C.V. | Results Avimex® resultados preliminares de la FASE 1 clínica del proyecto VACUNAL PATRIA® com.mx ↗
Los resultados preliminares de la Fase Clínica I del proyecto vacunal Patria señalan que es un biológico seguro y con potencial de inmunogenicidad en seres humanos. |
| 2021-11-12 | Laboratorio Avi-Mex, S.A. de C.V. | Results Avimex® anuncia la publicación de datos Preclínicos en cerdos de la VACUNA PATRIA® (AVX/COVID-12) com.mx ↗
Las pruebas en cerdos de la vacuna mexicana Patria® mostraron que tanto la administración intranasal como intramuscular, así como una combinación de ambas, induce respuestas robustas de anticuerpos, incluyendo contra las variantes de interés. |
All press releases naming this drug 7 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVX/COVID-12 | “we conducted a phase II clinical trial to evaluate the safety and immunogenicity of the locally manufactured AVX/COVID-12 "Patria" (AVX) vaccine as a booster dose.” PMID 39527880 ↗ Nov 2024 |
| Known as | AVX | “we conducted a phase II clinical trial to evaluate the safety and immunogenicity of the locally manufactured AVX/COVID-12 "Patria" (AVX) vaccine as a booster dose.” PMID 39527880 ↗ Nov 2024 |
| Known as | Patria | “we conducted a phase II clinical trial to evaluate the safety and immunogenicity of the locally manufactured AVX/COVID-12 "Patria" (AVX) vaccine as a booster dose.” PMID 39527880 ↗ Nov 2024 |
| Modality | Vaccine | “AVX/COVID-12 "Patria" recombinant Newcastle disease virus vaccine” PMID 39527880 ↗ Nov 2024 |
| Route | Intramuscular | “administered either intramuscularly (IM) or intranasally (IN)” PMID 39527880 ↗ Nov 2024 |
| Route | Intranasal | “administered either intramuscularly (IM) or intranasally (IN)” PMID 39527880 ↗ Nov 2024 |